TheEdgeResearch
Home / Stocks / ATTO

Attovia Therapeutics, Inc. (ATTO)

NASDAQ Healthcare Biotechnology
$15.10 ▼ -3.08%
Market Cap
$690.3M
Sector
Healthcare
Industry
Biotechnology
Beta
0.00
52-Wk Range
12.94-28
CEO
Tao Fu
Country
US
Currency
USD

Attovia Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Carlos, CA, US. The stock last traded at $15.10, down 3.08% on the session, giving a market capitalisation of $690.3M. On trailing twelve-month figures it carries a trailing P/E of -8.39, a net margin of -5477.2%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-8.39
Price / Sales
479.35
Price / Book
11.15
EV / EBITDA
-6.84
Gross margin
32.8%
Operating margin
-5945.5%
Net margin
-5477.2%
Return on equity
—
Debt / equity
0.01
Current ratio
34.66
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
50
IPO date
2026-08-05
Headquarters
San Carlos, CA, US
About Attovia Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Comparable companies

Attovia Therapeutics, Inc. is most often compared with the following Healthcare names:

ACRSAGMBALMSANABCNTBEVMNMLTXORKAQTTBZURA
More research on ATTO
ATTO technical analysis ATTO TheEdge Score Compare against peers
Open full interactive analysis & DCF →